VVector Bio, Inc. was founded in 2019 in Montreal, Canada to support R&D and preclinical studies in cell and gene therapy. The aim of the company is helping academic laboratories, hospitals, companies, and other institutions to bring faster to reality their innovative viral vector-based therapies in development. The company provides expert services to help you customize your viral vector carrier and also produce high virus vector yields for preclinical studies
AAV has been developed for the construction of viral vector candidates mainly for the purpose of gene therapy due to a number of attractive advantages. Advantages and drawbacks of AAV vector-mediated gene transfer are summarized below. Advantages: i) Great biosafety; the wild type AAVs are not known to cause disease in vivo, and most AAV genome elements have been removed for further security of gene delivery in vivo. ii) Low immunogenicity; AAV causes a mild immune response in vivo, providing support to their pathogenicity during gene delivery. iii) Broad range of infectivity. AAV can infect both dividing and quiescent cells in vivo, allowing gene delivery to a highly diverse range of cell types. 4) Stable expression. Long term gene delivery in vivo can be mediated by AAV. No integration into the genome.
Please contact us directly by email as indicated in our Home Page and we will provide a detailed response and personalized assistance to your research needs and inquiries.
the text of answer
the text of answer
the text of answer
VVECTOR BIO, Bridging Research and Clinic
VVector Bio offers excellent services for Adeno-associated virus (AAV), Lentivirus and Adenovirus production to support cell and gene therapy development
2020 VVECTOR BIO. All Rights Reserved
